Digestive Disease Week

Rezaie explains findings from his recent research connecting GLP-1RA use to aspiration pneumonia after endoscopy with deep sedation.

Fendrick explains how stool-based colorectal cancer screening tests can help alleviate the current colonoscopy backlog amid growing demand for the procedure.

A diagnosis of chronic kidney disease was approximately 3-times more likely in Crohn's disease than in ulcerative colitis.

In this Q&A, Levy discusses the current treatment landscape for PBC and what clinical trial data suggest about seladelpar’s potential for these patients.

Fendrick explains the value of additional modalities for colorectal cancer screening to combat the colonoscopy backlog and help patients get screened.

A retrospective analysis in the US found bariatric surgery lowers mortality rates and shortens hospital stays in patients admitted with NAFLD.

Interim results from the open-label, phase 3 study show seladelpar demonstrated clinically meaningful improvements in markers of cholestasis and liver injury.

Initial consultations by female gastroenterologists led to a significant reduction in subsequent healthcare utilization compared with male gastroenterologists.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

There is no additional risk of developing new cancers for patients treated with IBD medications.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

There was a reduction in medical costs that offset the increased pharmacy costs in the patients who were treated with rifaximin.

In 2022, dupilumab became the first treatment approved by the US Food and Drug Administration for the treatment of patients with EoE.

In the induction trial, guselkumab resulted in a higher rate of clinical remission, as well as symptomatic remission, clinical response, endoscopic improvement, and histo-endoscopic mucosal improvement at week 12.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Guselkumab induction treatment resulted in significantly greater proportions of patients achieving symptomatic remission, clinical response, endoscopy improvement, and histo-endoscopic mucosal improvement at week 12 and symptomatic remission at week 4 compared to placebo.

The lowest screening completion rate was in the colonoscopy invitation group at 14.5% and the patients offered a choice were more likely to complete screening of any kind, compared to either group of patients offered only 1 screening modality.

The mean number of required reinterventions was significantly lower in the patients who received a direct endoscopic necrosectomy at index session when compared with patients who received the step-up treatment approach.

There was a significant reduction in severity score for diarrhea, constipation, abdominal pain, epigastric pain, bloating, vomiting, and acid reflux in participants who reported digestive problem improvements followed by SIM01 treatment.

Regardless of a prior history of swallowed topical corticosteroids, dupilumab was proven to be an effective treatment in patients with eosinophilic esophagitis.

RBX2660 can be administered through a colonoscopy or rectally.

RBX2660 was originally approved by the FDA in 2022 and came to market in January 2023.

Rates of key safety events, such as malignancies and major adverse cardiovascular events, were comparable among patients receiving placebo and ustekinumab.

Recent studies have indicated that using adenoma per colonoscopy as a metric could help better forecast the risk of colon cancer.

Patients with IBD who were treated with advanced therapies who obtained clinical remission had 1.6 times more likely to maintain remission when compared with those who achieved clinical response without remission.